BellRing Brands (BRBR)
(Delayed Data from NYSE)
$57.24 USD
-0.44 (-0.76%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $57.24 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$57.24 USD
-0.44 (-0.76%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $57.24 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth D Momentum A VGM
Zacks News
BellRing Brands (BRBR) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
BellRing Brands (BRBR) delivered earnings and revenue surprises of 43.75% and 2.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Envista (NVST) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Envista (NVST) delivered earnings and revenue surprises of 6.82% and 0.77%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
BellRing Brands (BRBR) Reports Next Week: What Awaits?
by Zacks Equity Research
BellRing Brands (BRBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abbott (ABT) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 17.69% and 7.17%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
BellRing Brands (BRBR) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
BellRing Brands (BRBR) delivered earnings and revenue surprises of 8.70% and 1.74%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
ResMed (RMD) Q2 Earnings Meet Estimates
by Zacks Equity Research
ResMed (RMD) delivered earnings and revenue surprises of 0% and 3.92%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
BellRing Brands (BRBR) Reports Next Week: What Awaits?
by Zacks Equity Research
BellRing Brands (BRBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are These Medical Stocks Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
BellRing Brands (BRBR) Loses 11.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
BellRing Brands (BRBR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
LabCorp (LH) to Expand Nonclinical Development With New Buyout
by Zacks Equity Research
LabCorp's (LH) acquisition of Toxikon can expand its full-service drug development and medical device solutions portfolio.
BellRing Brands (BRBR) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
BellRing Brands (BRBR) delivered earnings and revenue surprises of -7.41% and 5.62%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Masimo (MASI) Reports SedLine's Psi & DSA Parameter Findings
by Zacks Equity Research
The study findings show that monitoring with Masimo (MASI) SedLine Brain Function Monitoring parameters during CEA surgery can reduce the risk of postoperative delirium.
Intuit (INTU) Readies to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Intuit (INTU) Q1 results are likely to reflect benefits from strong momentum in the online ecosystem, solid demand for tax products and revenue contribution from the Credit Karma business.
Should You Buy BellRing Brands (BRBR) Ahead of Earnings?
by Zacks Equity Research
BellRing Brands (BRBR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
NVIDIA (NVDA) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
NVIDIA's (NVDA) Q3 performance is likely to have benefited from strong demand for chips used in gaming consoles and data centers amid the work-and-learn-at-home and gaming waves.
Coupang (CPNG) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Coupang's (CPNG) third-quarter results are expected to reflect strength in its e-commerce business and momentum across Rocket fresh and Coupang eats.
Upstart (UPST) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Upstart's (UPST) third-quarter results are expected to reflect benefits from strong AI efforts and solid momentum across its platform.
ContextLogic (WISH) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
ContextLogic's (WISH) third-quarter results are likely to reflect gains from strength in ProductBoost and Logistics businesses.
fuboTV (FUBO) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
fuboTV's (FUBO) third-quarter results are expected to reflect strength across sports streaming offerings and solid online sports wagering momentum.
Fiverr (FVRR) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Fiverr's (FVRR) third-quarter 2021 results are expected to reflect gains from its international expansion, marketing efficiency and technology enhancements.
Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Is BellRing Brands (BRBR) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
What's in the Cards for Doximity (DOCS) in Q2 Earnings?
by Zacks Equity Research
Doximity's (DOCS) products like Doximity Dialer and Residency Navigator have been in focus and we expect both to have generated significant revenues during the fiscal second quarter.
Cardinal Health (CAH) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal first-quarter results are likely to reflect solid performance in the Pharmaceutical segment.
Fulgent Genetics (FLGT) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
The recent buyout of CSI Laboratories and strategic investments in early cancer screening are likely to have contributed to growth for Fulgent Genetics (FLGT).